Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**beta-peltatin** is a natural cyclolignan compound (molecular formula C22H22O8, CAS number 518-29-6) isolated primarily from the rhizomes of Podophyllum peltatum (mayapple) and other plant sources. It is structurally related to podophyllotoxin and α-peltatin, sharing the characteristic polycyclic core with methoxy and hydroxy substitutions[1][2][4]. Beta-peltatin possesses notable antitumor and antiviral activity; it acts as a cytotoxic compound and is a known inhibitor of cell division. Its mechanism of action is believed similar to other podophyllotoxin derivatives: inhibition of microtubule assembly via binding to tubulin, leading to mitotic arrest, and possibly some inhibition of DNA topoisomerase II, though direct evidence for topoisomerase II binding is less than for some derivatives[3][5]. Beta-peltatin has been studied in vitro for cytotoxic, antitumor, and antiviral properties but has not been developed as a marketed pharmaceutical[3][5]. It serves as a chemically interesting compound for the synthesis and study of podophyllotoxin-related anticancer agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-peltatin.